In-licensing

Which companies stand out post-ASCO?

Which companies stand out post-ASCO?

ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.

Pharmas to biotechs: let's make a deal

Pharmas to biotechs: let's make a deal

By

Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals.

Company news: Licensepalooza -- Janssen/Evotec, AstraZeneca/Link Medicine, Eisai/Verastem

J&J's Janssen unit inked a deal with Evotec AG and Harvard University to license a portfolio of diabetes drugs and biologics designed to trigger the regeneration of insulin-producing beta cells.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters